NCT06811727 CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients
| NCT ID | NCT06811727 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Ivan Šitum, MD |
| Condition | Severe Infection |
| Study Type | INTERVENTIONAL |
| Enrollment | 140 participants |
| Start Date | 2025-08-01 |
| Primary Completion | 2029-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 140 participants in total. It began in 2025-08-01 with a primary completion date of 2029-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Ceftazidime/avibactam (CZA) is an essential treatment option for managing infections caused by multidrug-resistant (MDR) gram-negative (G-) bacteria, including Klebsiella pneumoniae OXA-48 and carbapenem-resistant Pseudomonas aeruginosa. Critically ill intensive care unit (ICU) patients frequently exhibit altered pharmacokinetics (PK) of CZA, potentially compromising optimal PK/pharmacodynamic (PD) target attainment with standard dosing regimens. This study compares the efficacy of continuous infusion (CI) versus conventional intermittent dosing (ID) of CZA in critically ill ICU patients with severe infections caused by K. pneumoniae OXA-48 or P. aeruginosa. This single-centre, randomized, open-label trial will be conducted at a tertiary care hospital within the University Hospital Centre in Zagreb, Croatia, with a 1:1 allocation ratio. One hundred forty critically ill ICU patients requiring CZA treatment will be randomized to receive either ID (2 g/0.5 g every 8 hours over 2 hours) or an equivalent dose in CI (6 g/1.5 g continuously over 24 hours). The primary outcome is the microbiological success rate. Secondary outcomes include clinical success rate, time to symptom improvement, length of ICU and hospital stay, 28-day all-cause mortality, pathogen recurrence rate, time to weaning from mechanical ventilation, cumulative vasoactive-inotropic score, adverse events, and the ratio of ceftazidime plasma concentration to the pathogen's minimum inhibitory concentration (C/MIC). This trial seeks to provide evidence on the optimal administration strategy for CZA in critically ill ICU patients with severe infections due to MDR G- pathogens.
Eligibility Criteria
Inclusion Criteria: 1. General 1. Age above or equal to 18 years of age. 2. Able to provide informed consent personally or by his/her next of kin, as requested by the Ethics Committee. 2. Disease-specific 1. Critically ill patients requiring admission to the intensive care unit (medical or surgical). 2. Diagnosed with severe infections. 3. At least one microbiological sample positive for Klebsiella pneumoniae OXA-48 or Pseudomonas aeruginosa. 4. Requiring a prescription for ceftazidime/avibactam, by clinical judgement Exclusion Criteria: 1. General 1. Known or suspected hypersensitivity to ceftazidime/avibactam, excipients, or any other cephalosporin antibacterial agent. Severe hypersensitivity (e.g. anaphylactic reaction, severe skin reaction) to any other β-lactam antibacterial agent (e.g. penicillins, monobactams or carbapenems). 2. Withdrawal of informed consent. 3. Age above 85 years of age. 4. Female who is pregnant or breast-feeding. 5. Participation (i.e. signed informed consent) in any other interventional clinical trial of an approved or non-approved antibacterial agent within 30 days before screening. 6. Any disorder which, in the investigator's opinion, might jeopardize the participant's safety or compliance with the protocol. 2. Laboratory values 1\. Severe neutropenia before or during ceftazidime/avibactam administration. 3. Medical conditions 1. Death within 48 hours following randomization. 2. Concomitant acquired immunodeficiency syndrome. 3. Presence or history of malignant neoplasms or in situ carcinomas. 4. Duration of ceftazidime/avibactam administration is shorter than 72 hours.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06811727 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Severe Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06811727 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06811727 currently recruiting?
Yes, NCT06811727 is actively recruiting participants. Contact the research team at ivsitum@gmail.com for enrollment information.
Where is the NCT06811727 trial being conducted?
This trial is being conducted at Zagreb, Croatia.
Who is sponsoring the NCT06811727 clinical trial?
NCT06811727 is sponsored by Ivan Šitum, MD. The trial plans to enroll 140 participants.